公开(公告)号：WO2021179094A1

公开(公告)日：2021-09-16

申请号：PCT/CA2021/050339

申请日：2021-03-15

Applicant: UNIVERSITY OF NEW BRUNSWICK

Inventor： MURUGESAN, Alli ,  REIMAN, Anthony

IPC: A61K31/216 ,  A61P35/00 ,  C07C69/732

Abstract: Methods, compositions and uses of combination treatments for cancers are disclosed including administering to the patient a therapeutically effective amount of CAPE or CAPE analog(s), and CAPE or CAPE analog(s) in combination with a histone deacetylase inhibitor or an Immunomodulatory class of compounds or Sp1 or a MYC regulating agent, wherein administration of such combinations reduces the number or growth of cancer cells or the tumor burden or tumour growth in the patient, thereby treating the patient.

公开(公告)号：WO2020210920A1

公开(公告)日：2020-10-22

申请号：PCT/CA2020/050523

申请日：2020-04-20

Applicant: UNIVERSITY OF NEW BRUNSWICK ,  UNIVERSITÉ DE MONCTON

Inventor： MURUGESAN, Alli ,  REIMAN, Anthony ,  TOUAIBIA, Mohamed

IPC: A61K31/216 ,  A61K31/075 ,  A61K31/12 ,  A61P35/00 ,  C07C235/34 ,  C07C43/178 ,  C07C49/248 ,  C07C69/732 ,  C07C69/734

Abstract: Methods, compositions and uses for inhibiting the growth in blood cancer cells in a patient with one or more of a caffeic acid phenpropyl ester (GL8) analogue selected from the group consisting of As26, J229, J91, LL27, LL23, HM7, As25, MT26, and J205. The blood cancer cells can be myeloma, lymphoma and leukemia cells. The methods, compositions and uses can be in conjunction with the use of an IMiD to treat a patient. The compositions can include a pharmaceutically acceptable carrier, adjuvant or vehicle, a pharmaceutically acceptable salt or dietary supplement.

公开(公告)号：WO2017075702A1

公开(公告)日：2017-05-11

申请号：PCT/CA2016/051273

申请日：2016-11-02

Applicant: UNIVERSITY OF NEW BRUNSWICK

Inventor： REIMAN, Anthony ,  MURUGESAN, Alli

IPC: A61K38/17 ,  A61P19/08 ,  C07K14/47 ,  C07K7/08

CPC classification number: C07K14/47 ,  A61K38/00

Abstract: Described are methods and associated uses for the treatment of resorptive bone disease using peptides comprising all of part of the C-terminal portion of soricidin. Also described are methods and associated uses for inhibiting osteoclast activity and/or bone resorption using the peptides.

Abstract translation: 描述了使用包含全部部分的杀in素的C端部分的肽治疗再吸收性骨疾病的方法和相关用途。 还描述了使用肽抑制破骨细胞活性和/或骨吸收的方法和相关用途。